Privi Speciality Chemicals Shareholders Clear Amalgamation Scheme

Privi Speciality Chemicals Limited shareholders have officially approved the Scheme of Amalgamation involving its subsidiaries, Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited. The vote follows an NCLT order from September 2026, consolidating the entities under the transferee company, Privi Speciality Chemicals.

Reader Takeaway: The merger streamlines corporate structure by combining specialty chemical units under one listed entity for improved operational efficiency.

What just happened

On October 27, 2026, Privi Speciality Chemicals held an NCLT-convened meeting via video conferencing. Shareholders voted on the merger of two transferor companies: Privi Fine Sciences and Privi Biotechnologies. The motion passed with the requisite majority based on the final report from the appointed scrutinizer, Mrs. Dipti Arpit Nagori.

Why this matters

The amalgamation is a strategic move to centralize the group's chemical manufacturing and R&D capabilities. By integrating these subsidiaries, Privi Speciality Chemicals aims to simplify its corporate architecture and optimize resource allocation across its specialty chemical product lines.

Procedural details

The meeting lasted approximately 43 minutes, chaired by Mr. Mohan Prasad Tiwari. A total of 57 members attended the virtual proceedings. Shareholders were given the opportunity to participate in a Q&A session where management addressed specific queries regarding the integration of the business units.

What happens now

Following this approval, the company will finalize the formal filing of the scrutinizer’s report with the stock exchanges and update its corporate website. The merger will now proceed toward final legal sanctioning by the relevant authorities in accordance with the NCLT framework.